Johnson and Johnson Stock Plunges 6% As Medical Device Sales Miss Wall Street Forecasts
Johnson & Johnson (JNJ) reported Q3 revenue of $25.4B, beating estimates, but shares fell 6% due to weak MedTech sales of $8.6B, missing forecasts. Pharmaceutical sales rose 7.7% to $16.76B. The company raised its full-year outlook and plans a potential spin-off of its orthopedics unit. According to the company, a talc settlement and deal costs of $7B impacted earnings.
How this was made
The 30-second read
Why it matters
The earnings miss in MedTech drives immediate negative sentiment, though pharma growth remains robust.
Market read
The earnings release is material for JNJ and its peers; the stock move reflects market reaction to segment performance.
What to watch
Potential upside from the upcoming orthopedics spin‑off and a mid‑2027 timeline.
Background
Johnson & Johnson reported Q3 results with revenue beating estimates but a miss in its MedTech segment, leading to a stock decline.
Ticker impact
Q3 earnings beat revenue estimates but MedTech sales missed forecasts, causing a 6% stock drop.
likely pressure as the market prices in the MedTech sales miss.
The earnings release is the first report of the MedTech miss; the share price already fell 6% on the news.
Market effects
Device makers such as Boston Scientific and Intuitive Surgical may see modest weakness.
U.S. healthcare stocks could see slight pullback; overseas MedTech exposure may be re‑priced.
Limited to healthcare sector; broader market impact minimal.
Counterpoint
Strong pharmaceutical growth could offset device weakness, supporting a longer‑term rebound.
Key entities
- companyJohnson & Johnson
US‑listed healthcare conglomerate.
